FDA Approves Bosutinib for Pediatric Patients with Chronic Myelogenous Leukemia
September 27, 2023 -- On September 26, 2023, the Food and Drug Administration approved bosutinib (Bosulif, Pfizer) for pediatric patients 1 year of age and older with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) that is newly diagnosed... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 27, 2023 Category: Drugs & Pharmacology Source Type: news
FDA Approves Bosutinib for Children With CML FDA Approves Bosutinib for Children With CML
The agency approved the tyrosine kinase inhibitor for pediatric patients with chronic phase Ph+ chronic myelogenous leukemia that is newly diagnosed or resistant or intolerant to prior therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 27, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Proteinuria Higher With Dasatinib Exposure in Chronic Myelogenous Leukemia
WEDNESDAY, Sept. 20, 2023 -- For patients with chronic myelogenous leukemia (CML) receiving tyrosine-kinase inhibitor therapy, exposure to dasatinib is associated with increased odds of proteinuria, according to a study published online in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2023 Category: Pharmaceuticals Source Type: news
Early Major Response to Ponatinib in Pretreated CML Portends Better Outcomes
(MedPage Today) -- HOUSTON -- An early molecular or cytogenetic response correlated with better long-term survival in heavily pretreated chronic-phase chronic myeloid leukemia (CML) treated with the BCR-ABL inhibitor ponatinib (Iclusig), a post... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 8, 2023 Category: Hematology Source Type: news
Episode 4: The Past, Present, and Future of Chronic Myeloid Leukemia Episode 4: The Past, Present, and Future of Chronic Myeloid Leukemia
Drs Michael J. Mauro and Michael W. Deininger discuss the evolution of chronic myeloid leukemia, better access to treatment, improved global cure rates, and a clearer definition of the word cure.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 29, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Episode 3: Developments and Challenges in Chronic Myeloid Leukemia Episode 3: Developments and Challenges in Chronic Myeloid Leukemia
Drs Michael J. Mauro and Jorge E. Cortes discuss developments in the therapeutic landscape of chronic myeloid leukemia, complexities of resistance, and the potential for treatment-free remission.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 27, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Aurobindo Pharma arm signs pact with Medicines Patent Pool to develop anti-cancer drug
India's Aurobindo Pharma has announced that its subsidiary Eugia Pharma Specialities has signed a voluntary sub-licensing agreement with Medicines Patent Pool to develop and market an anti-cancer drug- Nilotinib capsules. Nilotinib capsules are used for the treatment of chronic myeloid leukemia. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 23, 2023 Category: Pharmaceuticals Source Type: news
Off Their Pricey CML Meds, Many Thrive Off Their Pricey CML Meds, Many Thrive
Over the last few years, physicians have experimented with taking patients with chronic myeloid leukemia (CML) off their drugs entirely, and the results are promising.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 26, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Adherence to Quality Indicators Low in Chronic Myeloid Leukemia
Compliance with diagnostic and therapeutic indicators was 83 and 78 percent, while compliance with monitoring indicators was lower (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 23, 2022 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news
Adherence to Quality Indicators Low in Chronic Myeloid Leukemia
WEDNESDAY, Nov. 23, 2022 -- For newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients, adherence to guideline-based quality indicators is low, according to a study published online Nov. 11 in Leukemia& Lymphoma.
Genevi ève... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 23, 2022 Category: Pharmaceuticals Source Type: news
Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML?
(MedPage Today) -- For patients with chronic-phase chronic myeloid leukemia (CML), a response-based dose-reduction strategy for ponatinib (Iclusig) may limit its toxicity while maintaining or improving efficacy, a retrospective study suggested... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 29, 2022 Category: Hematology Source Type: news
Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
BOSTON and ATLANTA, Aug. 26, 2022 -- (Healthcare Sales & Marketing Network) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parki... Biopharmaceuticals, Oncology, FDA Inhibikase Therapeutics, imatinib , Chronic Myelogenous Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2022 Category: Pharmaceuticals Source Type: news
'Rogue' Online Pharmacies Are Dispensing Cancer Drugs
(MedPage Today) -- Dozens of illegitimate online pharmacies are selling imatinib, an oral chemotherapy drug for chronic myeloid leukemia (CML), putting patients at risk for toxicities and treatment failures, researchers found.
Of 44 online pharmacies... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 29, 2022 Category: American Health Source Type: news
Division of Hematologic Malignancies 1 (DHM1)
regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologic Licensing Applications (BLAs) for Acute Leukemia and Myelodysplasia and Chronic Myeloid Leukemia. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 10, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Alembic gets USFDA nod for cancer treatment drug
Dasatinib Tablet is indicated for the treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 10, 2022 Category: Pharmaceuticals Source Type: news
